Minoxidil vs RU-58841
A side-by-side research comparison of Minoxidil and RU-58841 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Minoxidil | RU-58841 |
|---|---|---|
| Full name | Minoxidil (Rogaine) | RU-58841 (PSK-3841) |
| Category | Hair Growth | Hair Growth |
| Status | FDA Approved (OTC) | Research compound |
| Mechanism | Opens ATP-sensitive potassium channels in vascular smooth muscle and hair follicle cells. Increases blood flow and nutrient delivery to follicles. Prolongs anagen (growth) phase and stimulates VEGF expression for neovascularization around follicles. | Non-steroidal androgen receptor antagonist with high binding affinity. Applied topically, penetrates to dermal papilla cells where it blocks DHT-AR complex formation, preventing transcription of hair-miniaturizing genes without systemic antiandrogen effects. |
| Molecular weight | 209.25 Da | 369.34 Da |
| Half-life | ~4 hours (systemic); active in follicle for 22h | ~1 hour (in skin/plasma); active at receptor for 8-12h |
| Bioavailability | ~95% oral; topical: local depot effect | Topical only - minimal systemic absorption |
| Typical dose | 5% topical (1mL 2x/day) or 2.5-5 mg oral | 50-100 mg in 1mL vehicle |
| Frequency | Twice daily (topical) or once daily (oral) | Daily application to scalp |
| Route | Topical solution/foam or oral tablet | Topical (dissolved in ethanol/PG vehicle) |
Minoxidil reported benefits
- Stimulates new hair growth
- Works independently of DHT pathway
- OTC availability
- Effective for both sexes
- Prolongs anagen phase
- Can combine with any other treatment
RU-58841 reported benefits
- Local anti-androgen (no systemic effects)
- No sexual side effects
- DHT blocking at follicle level
- Can combine with oral finasteride
- Fast-acting (visible in weeks)
Related comparisons
Research and educational reference only. Not medical advice.